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Introduction
An international symposium on albuminuria entitled
“The Role of Albuminuria in Health and Disease: Pre-
dicting Outcomes and Target for Therapy” was held in
New York from May 16 to 18, 2004. The goal of this sym-
posium was to present the (global) evidence that details
the role of albuminuria as an independent marker for
renal and cardiovascular disease. Additionally, the role
of albuminuria as an independent therapy target for pri-
mary and secondary prevention of renal and cardiovas-
cular disease development was addressed. The invited
participants, both speakers and audience, were interna-
tional key opinion leaders on this topic from the fields
of nephrology, cardiology, endocrinology, hypertension,
and epidemiology. Representatives of national and in-
ternational societies and governmental bodies from both
the United States and Europe also participated in this
meeting.
The meeting was presented by the National Kidney
Foundation U.S. (NKF), in association with the Interna-
tional Society of Nephrology (ISN), and supported by
the American Diabetes Association (ADA), American
Society of Hypertension, Inc. (ASH), American Society
of Nephrology (ASN), European Society of Hyperten-
sion (ESH), International Diabetes Federation (IDF),
Juvenile Diabetes Research Foundation International
(JDRF), and the following councils of the American
Heart Association (AHA): Council on Clinical Cardiol-
ogy, Council on Cardiovascular Nursing, Council on High
Blood Pressure Research, and the Council on Kidney in
Cardiovascular Disease. The symposium was made pos-
sible by an unrestricted educational grant from AusAm
Biotechnologies, Inc.
The meeting reached a clear consensus. Specifically, al-
buminuria is an important independent risk marker for
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both cardiovascular and renal disease. The pathophysio-
logic mechanisms behind this predictive relationship are
still not fully understood, but much evidence appears to
link any level of albuminuria to a generalized loss of vas-
cular (endothelial) function in many organs, providing a
common mechanism for augmented cardiovascular and
renal risk in patients with microalbuminuria. Clearly, inhi-
bition of the renin-angiotensin-aldosterone-system is an
instrument to reduce albuminuria at all levels, whether it
is preventing its development in those who are normoal-
buminuric or have overt proteinuria. New and intrigu-
ing data were presented, showing that the magnitude of
albuminuria reduction is associated with cardiovascular
and renal protection in advanced disease states, as well
as in otherwise healthy individuals. This linkage between
lowering albuminuria and disease progression makes al-
buminuria an interesting new target for therapy.
The consensus also stated that new guidelines should
be formulated covering all areas of expertise, including
how and when urinary albumin should be measured, and
with what method. How does albuminuria as a cardio-
vascular risk marker relate to reduced GFR as a cardio-
vascular risk marker? In addition, intervention trial(s)
should be designed such that they will link therapeutic
targeting of albuminuria reduction to cardiovascular and
renal protection.
This supplement is a state of the art collection of the
data presented at this stimulating multidisciplinary meet-
ing. We hope this focus of international expertise will
serve as a stimulus for future meetings and insightful re-
search on this topic.
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